Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/4/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -1.90% | +2.37% | +69.11% | +110.88% | 73.45B | |
| +0.87% | +17.17% | +53.05% | +95.59% | 62.99B | |
| +1.71% | -1.44% | +2.66% | +501.29% | 28.05B | |
| -1.40% | +4.18% | +54.52% | +19.60% | 25.42B | |
| +21.96% | +21.90% | +0.51% | +2.50% | 23.3B | |
| +2.28% | +7.98% | +42.75% | -12.34% | 19.45B | |
| 0.00% | -4.11% | +243.99% | +423.83% | 18.16B | |
| -3.50% | -0.95% | +17.17% | +534.55% | 16.53B | |
| +2.39% | +5.96% | +44.04% | +157.77% | 13.16B | |
| Average | +0.08% | +2.74% | +58.64% | +203.74% | 31.17B | |
| Weighted average by Cap. | -0.16% | +4.39% | +57.10% | +168.10% |
Employees
51
